FDA Approves Lytgobi (futibatinib) for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

Lytgobi (pronounced“light-GOH-bee”) delivered an objective response rate of 42% and median duration of response of 9.7 months in the primary analysis of the pivotal clinical trial. Lytgobi covalently binds to FGFR2 and inhibits the...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news